28 January 2026 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces the publication of a peer-reviewed paper from the POLB 001 LPS human challenge trial in Frontiers in Immunology. Read more…
Lund, Sweden, 26 January, 2026. Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA), will publish its year-end report for January – December 2025 on Wednesday 11 February, 2026. Interested parties may join the Company’s quarterly conference call on the same date at 14:00 CET / 8:00 AM EST. The event will be hosted by Renée Aguiar-Lucander, CEO, Evan Ballantyne, CFO, […]
Philanthropic partners invest US$60 million to support collaborative research to accelerate the discovery of next-generation antibiotics The Gates Foundation, Novo Nordisk Foundation, and Wellcome today awarded a total of US$60 million in new grant funding over the next three years to research teams around the world exploring novel approaches to antibiotic discovery to deal with […]
Unique platform designed to engage pro-resolution responses to restore immune homeostasis in inflammatory disorders without broad immuno-suppression. Cambridge, MA, USA, January 22, 2026 – Resolve M Therapeutics, Inc., the biotech aiming to build the world’s first comprehensive pro-resolution platform for target ID, validation and drug discovery for the treatment of inflammatory diseases, has announced its […]
Financing co-led by Octopus Ventures and new investor Amplify Bio Company readies its first-in-human clinical trial of ITOP1, a precision cancer vaccine designed to prevent recurrence in oesophageal cancer Oxford, UK – 21 January 2026 – Infinitopes, a clinical-stage cancer vaccine biotechnology company, today announced the successful completion of the second close of its seed […]
